Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 3Active not recruiting 3Completed 2Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 172Glioblastoma 72Gliosarcoma 70Brain Neoplasms 41Osteosarcoma 40Neoplasms 40Astrocytoma 38Recurrence 35Melanoma 33Oligodendroglioma 32Gastrointestinal Stromal Tumors 31Breast Neoplasms 31Glioma 30Lymphoma 29Dendritic Cell Sarcoma, Interdigitating 29Precursor Cell Lymphoblastic Leukemia-Lymphoma 28Neoplasm Metastasis 28Central Nervous System Neoplasms 27Burkitt Lymphoma 26Bone Neoplasms 26Ovarian Neoplasms 25Colorectal Neoplasms 24Neuroblastoma 22Lymphoma, Non-Hodgkin 22Lymphoma, Large B-Cell, Diffuse 22Stomach Neoplasms 21Sarcoma, Ewing 21Lung Neoplasms 19Leukemia, Myeloid, Acute 19Leukemia 19

Interventions

ganitumab 1Receptor Protein-Tyrosine Kinases 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Rhabdomyosarcoma, Embryonal × Sarcoma × Clear all
NCT03041701 2022-04-14

Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
14 enrolled 17 charts
Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡